2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly and Co. (LLY) based on the provided data.

**1) Return Rate Comparison and Analysis**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that develops and markets a wide range of pharmaceutical products.
*   **LLY Cumulative Return:** 281.99%
*   **VOO (S&P 500) Cumulative Return:** 105.07%
*   **Divergence:**
    *   Current: 176.9
    *   Relative Divergence: 83.1

**Analysis:**

Eli Lilly has significantly outperformed the S&P 500. The current divergence of 176.9 indicates a substantial difference in cumulative returns. The relative divergence of 83.1 suggests that the current outperformance is positioned in the upper range of its historical divergence from the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2016-2018  | 46.0% | 68.7% | 17.0% | 0.7  | 103.7  |
| 2017-2019  | 71.0% | 68.7% | 29.0% | 0.7  | 117.8  |
| 2018-2020  | 107.0% | 79.5% | 75.0% | 0.7  | 151.4  |
| 2019-2021  | 130.0% | 79.5% | 54.0% | 0.7  | 247.6  |
| 2020-2022  | 162.0% | 79.5% | 143.0% | 0.7  | 328.0  |
| 2021-2023  | 180.0% | 80.2% | 152.0% | 0.5  | 522.6  |
| 2022-2024  | 215.0% | 81.2% | 184.0% | 0.6  | 692.1  |
| 2023-2025  | 212.0% | 84.6% | 144.0% | 0.7  | 963.4  |

**Analysis:**

*   **CAGR:** Compound Annual Growth Rate is consistently high, demonstrating strong growth over various 3-year periods.
*   **MDD:** Maximum Drawdown has increased over the periods, indicating potentially increased risk (volatility) as the stock price has grown.
*   **Alpha:** Consistently positive and very high, suggesting LLY has significantly outperformed its benchmark (risk-adjusted return). The higher the alpha, the better the stock's performance relative to the risk taken.
*   **Beta:** Relatively stable and below 1, indicating that LLY is less volatile than the market (S&P 500).
*   **Cap(B):** Market capitalization has experienced substantial growth, indicating the company is expanding its market presence.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 1074.68
*   **Previous Close:** 1079.75
*   **Change:** -0.47
*   **5-day SMA:** 1077.578
*   **20-day SMA:** 1044.565
*   **60-day SMA:** 964.4222

**Analysis:**

The stock price has experienced a slight decrease recently. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, which generally indicates an upward trend, although the recent slight decrease might signal a short-term correction.

**3) RSI, PPO, Divergence, and Expected Return**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI:** 78.60 (Overbought territory)
*   **PPO:** -0.1369
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 1.1 (+): 단기상승 (Short-term increase)
*   **Expected Return:** 171.0%

**Analysis:**

*   The MRI suggests a favorable investment environment.
*   The RSI indicates the stock is currently overbought, which could lead to a price correction in the short term.
*   The PPO is slightly negative.
*   The hybrid signal suggests to buy and allocate all current cash to the position.
*   The increase in relative divergence indicates a short-term upward momentum.
*   The high expected return suggests that long-term investment could yield substantial profits, relative to the S\&P500.

**4) Recent News & Significant Events**

*   **Weight-loss Pill Pricing & Insider Filing:** Focus on obesity drug pricing.
*   **VIRGINIA RETIREMENT SYSTEMS ET Al Sold Shares:** Institutional selling might put some downward pressure on the stock.
*   **LLY a Top Stock Split Candidate:** Positive sign, often indicating management believes the stock is highly valued and accessible to a broader investor base.
*   **Futures Fall; Seven Stocks Near Buy Points:** General market sentiment.
*   **Why Eli Lilly (LLY) Stock Is Trading Up Today:** Addresses specific daily movements.

**Analysis:**

The news highlights both positive and negative factors. The focus on weight-loss drugs suggests a potential growth area for Eli Lilly. However, institutional selling and general market concerns could create short-term headwinds. A potential stock split is a positive sign.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price:** $1093.22 (avg) / $1500 (high) / $770 (low)
*   **Recent Rating Changes:** Not specified.

**Analysis:**

Analysts are generally positive on Eli Lilly, with a "Buy" consensus and an average target price slightly above the current price. The high target suggests some analysts see substantial upside potential.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

**Analysis:**

Both EPS and Revenue are demonstrating a strong upward trend, indicating solid growth and profitability. The anomaly (1.08, 11.44) could be a repeat or an error in the data, either way the remaining data provides a solid overview.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $23.79B    | 23.46%    |
| 2025-06-30   | $18.27B    | 30.98%    |
| 2025-03-31   | $15.76B    | 17.50%    |
| 2024-12-31   | $14.19B    | 31.07%    |
| 2024-09-30   | $14.24B    | 6.81%     |

**Analysis:**

*   **Revenue:** Consistently increasing, demonstrating solid top-line growth.
*   **Profit Margin:** Extremely high and stable, indicating efficient cost management and strong pricing power.
*   **Equity:** Growing over time, reflecting increased shareholder value.
*   **ROE:** Generally strong, indicating good profitability relative to equity. The large fluctuations in ROE might warrant further investigation.

**7) Comprehensive Analysis (Summary)**

Eli Lilly has demonstrated exceptional performance, significantly outperforming the S\&P 500. Strong revenue and earnings growth, high profit margins, and positive analyst ratings support a bullish outlook.  The company's focus on weight-loss drugs provides a potential catalyst for future growth.

**However, there are some points to consider:**

*   **Overbought RSI:** The stock might be due for a short-term correction.
*   **Institutional Selling:**  Selling by institutional investors could create some downward pressure.
*   **High Valuation:** The high valuation might make the stock vulnerable to market corrections.
* **Inconsistencies:** Inconsistencies in the earnings data should be validated against primary sources

**Overall:**

The data suggests that Eli Lilly is a strong company with excellent growth prospects. While some short-term risks exist, the long-term outlook appears positive. The strong fundamentals and positive analyst sentiment make it a potentially attractive investment, but investors should be aware of the potential for short-term volatility and conduct their own due diligence before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.